证券代码：000661 证券简称：长春高新 公告编号：2025-053 长春高新技术产业（集团）股份有限公司 监事会议事规则 本规则经 2024 年年度股东大会审议通过 2025 年 5 月修订 第二条 公司设立监事会。监事会依据《公司法》等法律法规 和公司章程赋予的权利行使监督职能。 第三条 本规则对公司全体监事、监事会指定的工作人员、列 席监事会会议的其它有关人员都具有约束力。 第二章 监事会的组成和产生 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 监事会的组成和产生 | 1 | | 第三章 | 监事的职责和监事会的职权 | 2 | | 第四章 | 监事会的出席资格和费用 | 3 | | 第五章 | 监事会的举行 | 4 | | 第六章 | 监事会决议的公告和执行 | 5 | | 第七章 | 附则 | 6 | 第一章 总则 第一条 为规范公司监事会的议事方法和程序，保证监事会工 作效率，行使监事会的职权，发挥监事会的监督作用，根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司治理准则》（以 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-054 长春高新技术产业（集团）股份有限公司 独立董事制度 本规则经 2024 年度股东大会审议通过 2025 年 5 月修订 1 第三条 公司董事会成员中设独立董事三名，其中至少有一名会计专业人 士。 第二章 独立董事的任职资格与任免 | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 独立董事的任职资格与任免 | 3 | | 第三章 | 独立董事的职责与履职方式 | 6 | | 第四章 | 独立董事的履职保障 | 9 | | 第五章 | 独立董事年报工作制度 | 10 | | 第六章 | 附则 | 11 | 第一章 总则 第一条 为进一步完善长春高新技术产业（集团）股份有限公司（以下简称 "公司"）的法人治理结构，保护全体股东尤其是中小股东及利益相关者的利益， 促进公司的规范运作，根据中国证监会《上市公司独立董事管理办法》、《上市公 司治理准则》和《公司章程》、《董事会议事规则》等相关规定，结合公司实际情 况，特制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及公 司主要股东、实 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-050 长春高新技术产业（集团）股份有限公司 章 程 经公司 2024 年度股东大会审议通过 2025 年 5 月修订 | | | | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 党委 | 2 | | 第三章 | 经营宗旨和范围 | 5 | | 第四章 | 股份 | 6 | | 第五章 | 股东和股东会 | 9 | | 第六章 | 董事和董事会 | 25 | | 第七章 | 高级管理人员 | 38 | | 第八章 | 监事和监事会 | 40 | | 第九章 | 财务会计制度、利润分配和审计 | 42 | | 第十章 | 通知和公告 | 48 | | 第十一章 | 合并、分立、增资、减资、解散和清算 | 49 | | 第十二章 | 修改章程 | 53 | | 第十三章 | 附则 | 53 | 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组 织和行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中 华人民共和国证券法》（以下简称《证券法》）和其他有关规定，制定本章 程。 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7624.71 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.46% in the past month, 3.56% in the past three months, and 2.43% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI 300 Index, categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.5%), WuXi AppTec (15.98%), Pian Zai Huang (6.77%), Yunnan Baiyao (5.51%), Kelun Pharmaceutical (4.73%), New Horizon (3.69%), East China Pharmaceutical (3.68%), Shanghai Raist (3.39%), Changchun High-tech (3.33%), and Fosun Pharma (3.23%) [1] - The market segment of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.75% and the Shenzhen Stock Exchange accounts for 36.25% [2] - In terms of industry composition, chemical drugs account for 43.27%, pharmaceutical and biotechnology services for 21.11%, traditional Chinese medicine for 19.35%, and biological drugs for 16.27% [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are fixed until the next scheduled adjustment unless a temporary adjustment is required [2] - Special events affecting sample companies may lead to changes in industry classification, and companies that are delisted will be removed from the index [2]

Investment Rating - The report maintains a rating of "Buy" for the industry, indicating an expected relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [5][50]. Core Viewpoints - The report emphasizes that the industry is expected to see a bottoming out and gradual improvement, with a continued focus on innovation and AI as key growth drivers. The performance of the pharmaceutical sector has shown resilience, with a year-to-date return of 1.2%, outperforming the Shanghai Composite Index by 3.4% [7][12]. - The report suggests that the innovation trend in pharmaceuticals is likely to persist, with specific recommendations for companies such as Changchun High-tech, Sanofi, and Betta Pharmaceuticals, among others [7][12]. - The report highlights the potential of AI in pharmaceuticals and healthcare, indicating that this sector is just beginning to unfold, with opportunities in drug development, diagnostic assistance, and chronic disease management [8][13]. Summary by Sections Industry Overview - The pharmaceutical industry comprises 498 listed companies with a total market capitalization of 62,240.01 billion yuan and a circulating market value of 55,873.42 billion yuan [2][5]. Market Performance - The report notes that the Shanghai Composite Index rose by 2.00% while the pharmaceutical sector increased by 1.01%, ranking 26th among 31 sub-industries. Various sub-sectors, including medical devices and traditional Chinese medicine, also experienced gains [7][12]. Investment Opportunities - The report identifies several key areas for investment: 1. **Innovation Growth**: Focus on innovative drugs with strong technological attributes and ongoing policy support [7][12]. 2. **AI in Healthcare**: Emphasizing the emerging opportunities driven by AI in diagnostics and drug research [8][13]. 3. **Recovery in Distressed Sectors**: Highlighting potential recovery in CRO&CDMO and specialty raw materials due to improved industry policies and global order recovery [8][13]. Key Company Recommendations - The report recommends a focus on companies such as: - Changchun High-tech - Sanofi - Betta Pharmaceuticals - WuXi AppTec - Daan Diagnostics - Others in the AI and healthcare sectors [7][8][12][13].

Core Viewpoint - The financial report of Changchun High-tech shows a significant decline in both revenue and net profit, marking the end of an 18-year growth trend, leading to a sharp drop in stock price [2][4][24]. Group 1: Financial Performance - In 2024, the company's operating revenue was 13.47 billion yuan, a decrease of 7.55% compared to 2023, which was 14.57 billion yuan [3]. - The net profit attributable to shareholders was 2.58 billion yuan, down 43.01% from 4.53 billion yuan in 2023 [3]. - Basic earnings per share fell to 6.42 yuan, a decline of 42.73% from 11.21 yuan in the previous year [3]. - The total assets at the end of 2024 were 31.05 billion yuan, a slight increase of 1% from 30.74 billion yuan in 2023 [3]. Group 2: Market Dynamics - The decline in performance is attributed to the impact of centralized procurement policies, which led to significant price reductions for key products, particularly the long-acting growth hormone [12][14]. - The revenue from Jin Sai Pharmaceutical, a subsidiary, was 10.67 billion yuan, down 3.73%, with net profit dropping 40.67% to 2.68 billion yuan [12]. - The competitive landscape has intensified, with new entrants offering lower-priced alternatives, threatening Changchun High-tech's market position [19]. Group 3: Cost and Investment - The company faced increased costs, with R&D expenses rising by 25.75% to 2.17 billion yuan, driven by accelerated new product development [13]. - Sales expenses increased by 11.81% to 4.44 billion yuan due to a rise in sales personnel to cope with market competition [13]. - Management expenses also grew by 25.59% to 1.20 billion yuan, further squeezing profit margins [13]. Group 4: Future Outlook - Despite the current downturn, the company is focusing on innovation and international expansion, with 24 key products in clinical stages [20]. - The approval of new products, such as the recombinant follicle-stimulating hormone injection, is expected to contribute over 500 million yuan in revenue by 2025 [20]. - However, uncertainties remain regarding the sustainability of growth and the impact of ongoing competitive pressures and market conditions [24].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000661 证券简称：长春高新 公告编号：2025-048 长春高新技术产业（集团）股份有限公司 关于召开2024年度及2025年第一季度 网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）2024年年度报告、2025年第一季度报告已 于2025年4月21日披露，为便于广大投资者进一步了解公司2024年度及2025年第一季度的业绩和经营情 况，公司将召开网上业绩说明会与投资者进行交流。具体情况如下： 一、会议召开日期与时间 2025年5月14日（星期三）15:00-16:00 二、会议召开方式 本次说明会将在"全景网"平台采用网络远程文字问答方式举行。 董事长姜云涛先生，董事、副总经理李秀峰先生，独立董事李春好先生，副总经理、财务总监朱兴功先 生，董事会秘书李洪谕先生。 四、投资者参与方式 投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次业绩说明会。 五、投资者问题征集 为提升公司与投资 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-048 长春高新技术产业（集团）股份有限公司 关于召开 2024 年度及 2025 年第一季度 网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）2024 年年度 报告、2025 年第一季度报告已于 2025 年 4 月 21 日披露，为便于广大投资者进 一步了解公司 2024 年度及 2025 年第一季度的业绩和经营情况，公司将召开网 上业绩说明会与投资者进行交流。具体情况如下： 一、会议召开日期与时间 2025 年 5 月 14 日（星期三）15:00-16:00 二、会议召开方式 本次说明会将在"全景网"平台采用网络远程文字问答方式举行。 三、会议出席人员 董事长姜云涛先生，董事、副总经理李秀峰先生，独立董事李春好先生， 副总经理、财务总监朱兴功先生，董事会秘书李洪谕先生。 四、投资者参与方式 投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与 本次业绩说明会。 五、投资者问题征集 为 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The innovative drug sector is expected to continue its growth, supported by strong technological attributes and favorable policies, with commercial insurance and Class B medical insurance providing further catalysts [6][11] - The AI-driven medical and pharmaceutical industry is just beginning, with potential investment opportunities emerging in drug development, assisted diagnosis, and chronic disease care [6][11] - The report highlights a recovery in performance for certain segments, including CRO&CDMO and specialty APIs, driven by improved industry policies and global order recovery [6][11] Summary by Sections May Industry Investment Outlook - The innovative growth of drugs is supported by strong technology and ongoing policy support, with recommendations for companies like Changchun High-tech and Three Life Pharmaceuticals [11] - AI in medicine is expected to create numerous investment opportunities, particularly in diagnostics and medical services [11] - Recovery is anticipated in segments like CRO&CDMO, with companies such as WuXi AppTec and Tianyu Co. being highlighted for their potential [11] April Review and Analysis - The pharmaceutical sector saw a decline of 2.1% in April, outperforming the Shanghai Composite Index, which fell by 3.0% [12] - The report notes that innovative drugs are leading the market, with a positive outlook for the remainder of the year [12] - The report anticipates a gradual improvement in performance across various sub-sectors, with some beginning to show signs of recovery [12] Key Recommendations - The report recommends focusing on companies such as WuXi AppTec, Changchun High-tech, and Three Life Pharmaceuticals for potential growth [13] - It emphasizes the importance of monitoring the performance of companies in the AI and medical sectors, including Dian Diagnostics and Meinian Health [11][13] Financial Performance Overview - In 2024, the pharmaceutical sector is projected to see a revenue decline of 0.8% and a profit drop of 9.9%, with a further decline in Q1 2025 [16] - The report indicates that while some segments are under pressure, the innovative drug industry is thriving, with significant growth in exports and BD opportunities [16] - The overall cash flow for the pharmaceutical sector is expected to decline, with notable variations across different segments [24][25]

Core Viewpoint - The article discusses the growing market for growth hormone treatments in children, highlighting the increasing demand from parents who wish to enhance their children's height through medical interventions, despite the associated costs and potential side effects [20][21][23]. Group 1: Height Prediction and Growth Factors - A commonly accepted method for predicting a child's future height is based on the parents' heights, with a formula that includes a genetic baseline and a variable component that can be influenced by environmental factors [3]. - Key hormones affecting height during childhood include sex hormones and growth hormones, with the latter determining the growth rate [4]. Group 2: Market Dynamics and Consumer Behavior - The growth hormone market has evolved significantly over the past decade, with companies investing heavily in marketing and education to promote the use of growth hormones for children [17][19]. - The demand for growth hormone treatments has led to a substantial market, with some companies achieving annual revenues in the billions [19]. Group 3: Treatment Options and Costs - Common forms of growth hormone available in the market include powder, short-acting, and long-acting injections, with differences in administration frequency and pricing [5]. - The financial burden of growth hormone treatments can be significant, with families spending tens of thousands of yuan over the years for their children's height enhancement [15][16]. Group 4: Clinical Practices and Parental Expectations - Many parents are increasingly seeking growth hormone treatments for their children, often bringing them to clinics at younger ages than before, driven by societal pressures and personal aspirations [8][10]. - There is a notable trend of parents willing to invest heavily in treatments, reflecting a broader societal perception that height can influence social and economic outcomes [16][21]. Group 5: Regulatory and Market Challenges - The growth hormone market faces challenges such as regulatory scrutiny and price competition due to collective procurement initiatives, which have led to reduced profit margins for manufacturers [23]. - Despite the declining profitability for some companies, the persistent demand from parents for height enhancement treatments remains strong, indicating a complex market landscape [23].